Corofenam/CV is a next-generation oral β-lactam antibiotic developed to combat both chronic and acute infections. Engineered to deliver broad-spectrum coverage against multi-drug-resistant (MDR) bacteria, it is effective in treating:
Its dual-action mechanism ensures complete coverage against Streptococcus pneumoniae, delivering exceptional results where traditional antibiotics may fail. The oral formulation, administered every 12 hours, enhances compliance while minimizing systemic toxicity.
Composition
Indications
-
Multi-drug-resistant UTIs
-
Upper & Lower Respiratory Tract Infections
-
Soft Tissue Infections
-
Gynecological Infections
-
Infections caused by Streptococcus pneumoniae
Dosage
Product Variants & Pricing
| Formulation |
Pack Size |
MRP (INR) |
| Faropenem Sodium 200 mg |
1 × 10 Tabs |
₹1200/- |
| Faropenem Sodium 200 mg + Potassium Clavulanate 125 mg |
1 × 10 Tabs |
₹1500/- |
Scientific Insights
1. Broad-Spectrum Action Against Resistant Pathogens
Corofenam/CV targets Gram-positive, Gram-negative, aerobic, and anaerobic bacteria. The addition of Potassium Clavulanate inhibits β-lactamase enzymes, boosting Faropenem’s efficacy and ensuring reliable bacterial eradication in MDR cases.
2. Higher Potency at Lower Doses
Compared to Meropenem (12–24 mg/kg), Faropenem requires just 5–10 mg/kg, delivering better outcomes with lower toxicity. This allows for safer, long-term treatment—ideal for outpatient care.
3. Improved Safety Profile
Corofenam/CV exhibits minimal gastrointestinal side effects such as nausea or diarrhea. Its oral delivery improves absorption and compliance, reducing the need for hospitalization or injectable alternatives.
Why Choose Corofenam/CV?
-
Potent β-lactam + β-lactamase inhibitor combo
-
High efficacy against MDR strains
-
Convenient oral therapy every 12 hours
-
Safer than conventional carbapenems
-
Ideal for both general and complicated infections
